Inactive Instrument

Sharon Bio-Medicine Ltd.

Equities

532908

INE028B01029

Sharon Bio-Medicine Ltd. Approves Board Resignations

April 25, 2017 at 12:40 pm IST

Sharon Bio-Medicine Ltd. announced that board of Directors of the company at its meeting held on April 24, 2017, approved Mr. Harish Palecanda and Dr. Nivedita Patil has tendered their resignation as an Independent Directors on the board of the company with effect from April 01, 2017.

Latest news about Sharon Bio-Medicine Ltd.

Sharon Bio - Medicine Limited Announces Intimation Regarding Re-Commencement of Manufacturing Facility	21/03	CI
Innova Captab Limited acquired Sharon Bio - Medicine Limited.	02/23/02	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/23/30	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Sharon Bio - Medicine Limited Appoints Rakhi Makhloga as Company Secretary	24/23/24	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Innova Captab Reportedly Places Bid for Sharon Bio-Medicine	31/22/31	CI
Sharon Bio - Medicine Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	17/22/17	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	07/22/07	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	03/21/03	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2021	13/21/13	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	23/21/23	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/21/12	CI
Sharon Bio-Medicine Ltd. Reports Unaudited Earnings Results for the Quarter and Half Year Ended September 30, 2020	11/20/11	CI
Sharon Bio Medicine Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2020	11/20/11	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	26/20/26	CI
Sharon Bio-Medicine Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2019	14/20/14	CI
Sharon Bio-Medicine Ltd. Reports Earnings Results for the Second Quarter Ended September 30, 2019	14/19/14	CI
Sharon Bio Medicine Limited Reports Standalone Unaudited Earnings Results for the Quarter Ended June 30, 2019	14/19/14	CI
Sharon Bio-Medicine Ltd. Announces Audited Standalone Earnings Results for the Quarter and Year Ended March 31, 2019	24/19/24	CI
Sharon Bio-Medicine Ltd. Provides Update on USFDA Inspection at its API Facility	22/19/22	CI
Sharon Bio-Medicine Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018	14/19/14	CI
Sharon Bio-Medicine Ltd. Closes its Operations at API Plant	28/19/28	CI
Sharon Bio-Medicine Ltd. Appoints Komal Mota as Company Secretary & Compliance Officer	09/19/09	CI

Chart Sharon Bio-Medicine Ltd.

Duration

Period

More charts

Company Profile

Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology. The Company offers various Active Pharmaceutical Ingredients, including Ketoconazole, Trimetazidine Di HCI, Glimepiride, Eperisone HCI, Memantine HCI, Telmisartan, Nifedipine, Aripiprazole and Atomoxetine HCI. The Company offers various intermediate products, including Cis Bromo Benzoate, N-Acetyl-4(4-Hydroxy Phenyl) Piperazine, Cis Tosylate and Tri Ethyl Benzyl Ammonium Chloride. The Company also offers various services, including preclinical toxicology on small animals, chemical process development and scale up, formulation development, analytical method development, drug master file (DMF) and dossier preparation, and commercial manufacturing of intermediates, actives and finished dosages.

Sector

More about the company